FDA Approves Imbruvica for Pediatric Chronic Graft Versus Host Disease

FRIDAY, Aug. 26, 2022 -- The U.S. Food and Drug Administration has approved Imbruvica (ibrutinib) for pediatric patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
The approval was based on...